Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma
University of Chicago
Summary
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
Description
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment. The purpose of this research is to gather information on the safety and effectiveness of belantamab mafodotin,…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
1. Subject must be ≥ 18 years of age. 2. Life expectancy of more than three months. 3. Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 4. Subject must have adequate organ function, defined by clinically confirmed lab values set by the study team. 5. Female Subjects: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 6. Male Subjects: contraceptive should be used consistently with local regulations regarding the methods of contraception for those Subjects in cl…
Interventions
- DrugBelantamab mafodotin
Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)
- DrugCarfilzomib
Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15 Cycles 2-8: 56 mg/m2 on Days 1/8/15 Cycles 9+: 56 mg/m2 on Days 1/15
- DrugPomalidomide
3 mg Day 1-21 of 28-day Cycle
- DrugDexamethasone
Cycles 1-4: 40 mg Days 1/8/15/22 Cycles 5+: 20 mg Days 1/8/15/22
Location
- University of Chicago Medicine Comprehensive Cancer CenterChicago, Illinois